"Remission Induction" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapeutic act or process that initiates a response to a complete or partial remission level.
Descriptor ID |
D012074
|
MeSH Number(s) |
E02.860
|
Concept/Terms |
Remission Induction- Remission Induction
- Induction, Remission
- Inductions, Remission
- Induction of Remission
- Remission Inductions
|
Below are MeSH descriptors whose meaning is more general than "Remission Induction".
Below are MeSH descriptors whose meaning is more specific than "Remission Induction".
This graph shows the total number of publications written about "Remission Induction" by people in this website by year, and whether "Remission Induction" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 4 | 4 |
1995 | 0 | 17 | 17 |
1996 | 0 | 11 | 11 |
1997 | 0 | 11 | 11 |
1998 | 1 | 8 | 9 |
1999 | 0 | 7 | 7 |
2000 | 0 | 18 | 18 |
2001 | 0 | 8 | 8 |
2002 | 0 | 11 | 11 |
2003 | 0 | 14 | 14 |
2004 | 0 | 15 | 15 |
2005 | 1 | 13 | 14 |
2006 | 0 | 11 | 11 |
2007 | 1 | 16 | 17 |
2008 | 0 | 18 | 18 |
2009 | 0 | 16 | 16 |
2010 | 0 | 12 | 12 |
2011 | 1 | 21 | 22 |
2012 | 1 | 14 | 15 |
2013 | 0 | 15 | 15 |
2014 | 0 | 19 | 19 |
2015 | 0 | 16 | 16 |
2016 | 0 | 15 | 15 |
2017 | 0 | 13 | 13 |
2018 | 1 | 19 | 20 |
2019 | 2 | 17 | 19 |
2020 | 3 | 16 | 19 |
2021 | 0 | 13 | 13 |
2022 | 0 | 8 | 8 |
2023 | 0 | 18 | 18 |
2024 | 2 | 6 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Remission Induction" by people in Profiles.
-
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Blood Cancer J. 2024 Jul 08; 14(1):108.
-
Factors associated with long-term clinical outcome in microscopic colitis. Ann Med. 2024 Dec; 56(1):2365989.
-
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis. Leukemia. 2024 Jul; 38(7):1564-1569.
-
Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies. J Crohns Colitis. 2024 Apr 23; 18(4):493-505.
-
Real-World Outcomes of Dual Advanced Therapy in Children and Young Adults with Inflammatory Bowel Disease. Dig Dis Sci. 2024 May; 69(5):1826-1833.
-
Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension. J Crohns Colitis. 2024 Feb 26; 18(2):264-274.
-
Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts. Leukemia. 2024 02; 38(2):389-392.
-
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2024 Jan; 65(1):69-77.
-
Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label Study. J Crohns Colitis. 2023 Dec 30; 17(12):1897-1909.
-
Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease. Dig Dis Sci. 2024 Feb; 69(2):355-359.